Transcode Therapeutics Inc stock is traded at $1.49, with a volume of 12,777. It is down -1.32% in the last 24 hours and down -16.29% over the past month. TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Previous Close:
$1.51
Open:
$1.53
24h Volume:
12,777
Relative Volume:
0.57
Market Cap:
$25.23M
Revenue:
-
Net Income/Loss:
-$40.36M
P/E Ratio:
-
EPS:
-$48.65
Net Cash Flow:
-$21.40M
1W Performance:
-8.59%
1M Performance:
-16.29%
6M Performance:
-80.19%
1Y Performance:
-83.96%
1-Day Range:
$1.45$1.56
1-Week Range:
$1.45$1.72
52-Week Range:
$1.45$12.60
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-301-6857Address
6 LIBERTY SQUARE, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS